阜阳哪看痘坑好阜阳皮肤病医院中医医院,阜阳市那家医院治疗面部扁平疣好,阜阳痤疮大概要多少费用,阜阳市医院治疗灰指甲,阜阳哪个皮肤病好点,阜阳看皮肤科哪里好,阜阳的去痘印治疗哪家好

BEIJING, Dec. 28 (Xinhuanet) -- China started to run its own satellite positioning system, Beidou, on Tuesday as the country climbed the global tech ladder and challenged the monopoly of the West. Beidou, or Big Dipper, the domestic version of the US Global Positioning System (GPS), started providing navigation, positioning and timing data on a pilot basis to China and the neighboring area for free on Tuesday, Ran Chengqi, director of the China Satellite Navigation Office, said. The system, with 10 orbiting satellites, covers an area from Australia in the south to Russia in the north. Signals can reach the Xinjiang Uygur autonomous region in the west and the Pacific Ocean in the east, Ran said. With six more satellites to be launched next year, the system will cover a wider area and eventually the entire globe by 2020 with a constellation of 35 satellites, he said. The accuracy of the positioning service will also improve as more satellites orbit. During the trial run Beidou can offer positioning to within 25 meters but when the system is officially launched next year accuracy will be enhanced to within 10 meters, he said. With the system operational China is the third member of an elite group, along with the US and Russia, to develop a satellite navigation system. The US spent 20 years and more than billion on the GPS. Completed in 1994, the system has 24 navigation satellites and is widely used around the world. Beidou has its own unique features, Ran said. "It not only tells users where they are and what time it is but also allows users to tell others the information through short messages," Ran said, adding that this feature is being considered by other systems. Russia's Glonass system achieved a 24-satellite constellation in 1996 but succumbed to funding problems. The rebuilding of the Glonass system is almost finished and Russian media reported that the system resumed service earlier this month. The European Union and the European Space Agency are building the Galileo satellite navigation system. Japan and India also intend to build independent regional navigation systems. "Countries build their own systems because owning an independent satellite navigation system is important to economic development and national security," said Pang Zhihao, deputy editor-in-chief of the monthly publication Space International. There have long been concerns that the US might take its dominant GPS offline in certain international emergencies. Ran said that the Beidou system will be "helpful" to national defense. An "independent and controllable" satellite navigation system can guarantee national economic development as well as scientific and industrial strength, he said. China started to reduce its reliance on the GPS in 2000, when it sent an experimental pair of positioning satellites into orbit. But Ran stressed that Beidou is "built for the world", as the compatibility of various systems enhances reliability for users. "If you only use GPS there will be blind spots. But from demonstrations I saw recently, receivers that are compatible with Beidou will overcome these problems," he said. He encouraged enterprises at home and abroad to join the research and development of application terminals compatible with Beidou. The office put a test version of the system's Interface Control Document online on Tuesday, which is a technical document vital for the manufacturing and development of receivers and chips. The prospects for the country's satellite navigation industry look bright, experts said. Analysts estimated that around 2020 the industry's output will reach 0 billion globally, including 400 billion yuan ( billion) to 500 billion yuan from China. According to the 2011 Report on Application of Geosaptial Information in China released on Monday, the number of satellite navigation application terminals in China has grown from less than 100,000 in 2000 to more than 10 million in 2009. The number is expected to reach 340 million by 2015. An insider said a compatible receiver for car use costs 1,600 yuan to 3,000 yuan, higher than a GPS receiver. "Chips supporting both GPS and Beidou systems have been developed, and terminals have been produced. There are no technical hurdles for the industry," said Han Shaowei, CEO of Beijing-based Unicore Communications Inc, a major navigation chip and core component provider. Beidou application terminals have been put into use in vehicles, such as government cars in Guangdong province. Ran said that private terminal makers in Guangdong are testing their receivers on the road, and the products seem stable. "The price of the compatible terminals is expected to be slashed next year," he said.

OTTAWA, Oct. 3 (Xinhua) -- Many friends and colleagues of Canadian scientist Ralph Steinman reacted with shock when they learned on Monday that Steinman won the Nobel Prize for Medicine and Physiology three days after he died.Since 1974, Nobel Prizes are no longer awarded posthumously, but the Nobel Prize committee said that it had made its choice before Steinman's death.Many of Steinman's friends and colleagues said that they learned of Steinman's death at the same time that they learned of his Nobel Prize, which was awarded for a discovery Steinman made in 1973.Steinman, 68, discovered dendritic cells, which help regulate adaptive immunity, which purges invading microorganisms from the body. Dendritic cells activate T cells, which "remember" the DNA sequence of invading organisms and protect the body from later infections from the same disease."Their work has opened up new avenues for the development of prevention and therapy against infections, cancer and inflammatory disease," the citation said.Monday, the Nobel Committee defended its decision to award the prize to Steinman. "The decision to award the Nobel Prize to Ralph Steinman was made in good faith, based on the assumption that the Nobel Laureate was alive," the foundation said in a statement."The Nobel Foundation thus believes that what has occurred is more reminiscent of the example in the statutes concerning a person who has been named as a Nobel Laureate and has died before the actual Nobel Prize Award Ceremony."It is still unclear who will pick up Steinman's prize at the award ceremony later this year.Steinman, a cell biologist at Rockefeller University in New York City, died of pancreatic cancer on Friday. For more than four years, he had used his own immune therapy discoveries to extend his life."The news is bittersweet, as we also learned this morning from Ralph's family that he passed a few days ago," Rockefeller University President Marc Tessier-Lavigne said in a statement."We are all so touched that our father's many years of hard work are being recognized with a Nobel Prize," Steinman's daughter, Alexis, said in the statement. "He devoted his life to his work and his family, and he would be truly honored."Steinman's heirs will share the 1.5-million U.S. dollar prize with American genetics professor Bruce Beutler and French scientist Jules Hoffmann.Dr. Beutler is professor of genetics and immunology at The Scripps Research Institute in La Jolla, California. Dr. Hoffmann headed a research laboratory in Strasbourg, France, between 1974 and 2009 and served as president of the French National Academy of Sciences between 2007 and 2008."Ralph worked right up until last week," said Michel Nussenzweig, a collaborator of Steinman's at Rockefeller University. "His dream was to use his discovery to cure cancer and infectious diseases like HIV and tuberculosis. It's a dream that's pretty close."Steinman was born in 1943 in Montreal, Canada's second largest city, and studied chemistry and biology at McGill University in his hometown before receiving an MD from Harvard Medical School in Boston in 1968. He joined Rockefeller University in 1970 as a postdoctoral fellow."He was diagnosed with pancreatic cancer four years ago, and his life was extended using a dendritic-cell based immunotherapy of his own design," the university said in a statement.In a statement, Canadian Prime Minister Stephen Harper lauded the three winners of the Nobel for medicine and called the award " a fitting final tribute" to Steinman's life's work."Dr. Steinman shall be honored for all time with this achievement," Harper said. "Canadians will mourn his loss."

BEIJING/CHONGQING, Oct. 16 (Xinhua) -- A team of Chinese and American scientists have discovered the world's only evidence of co-existing human beings and dinosaur tracks in a remote county in southwest China's Chongqing Municipality, according to a paper published Saturday in the Geological Bulletin of China, a Chinese core academic journal.Qijiang County's Lianhua Baozhai, which means "Lotus Mountain Fortress" in Chinese, has a large number of dinosaur tracks as well as a well-preserved fortress and historical epigraph, forming a direct line of evidence that ancient Chinese people built a residence and lived there for a long time, said Xing Lida, one of three researchers with the project as well as a doctoral degree candidate with the Department of Biological Sciences of the University of Alberta in Canada.Chinese people could have lived here for more than 700 years, and the mud cracks, ripple marks and duck-billed dinosaur tracks were considered by them to be lotus leaf veins, water environment and lotus, respectively, which is why they named it the Lotus Mountain Fortress, Xing Lida told Xinhua."Research shows that dinosaur tracks impacted ancient Chinese place names and folklore, so place names and folklore can be major clues for us in tracing dinosaur tracks," Xing said.According to the paper, the Lotus Mountain Fortress dinosaur tracks, the largest track group of cretaceous dinosaurs in southwestern China, contains 350 to 400 footprints that had been preserved in many ways, including concave footprints, convex footprints and multilayered footprints.

WASHINGTON, Dec. 12 (Xinhua) -- British scientists have discovered a new way to target cancer through manipulating a master switch responsible for cancer cell growth. The findings, published Monday in the U.S. journal Cancer Cell, reveal how cancer cells grow faster by producing their own blood vessels.Cancer cells gain the nutrients they need by producing proteins that make blood vessels grow, helping deliver oxygen and sugars to the tumor. These proteins are vascular growth factors like VEGF -- the target for the anti-cancer drug Avastin. Making these proteins requires the slotting together of different parts of genes, a process called splicing.Scientists at the University of West England and the University of Bristol discovered that mutations in one specific cancer gene can control how splicing is balanced, allowing a master switch in the cell to be turned on. This master switch of splicing makes cancer cells grow faster, and blood vessels to grow more quickly, as they alter how VEGFs are put together.In experimental models, the researchers found that by using new drugs that block this master switch they prevented blood vessel growth and stopped the growth of cancers."The research clearly demonstrates that it may be possible to block tumor growth by targeting and manipulating alternative splicing in patients, adding to the increasingly wide armory of potential anti-cancer therapies," the authors said.

WASHINGTON, Nov. 7 (Xinhua) -- U.S. researchers have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.The findings, published Monday in the online edition of the Journal of Clinical Investigation, suggest that drugs targeting the brain and central nervous system could be a novel approach to treating diabetes."The brain is the body's only organ that needs a constant supply of glucose to survive, so it makes sense that it would have some say over how much glucose is produced," said study leader Meredith Hawkins, professor of medicine and director of the Global Diabetes Initiative at Yeshiva University, in a statement. "This role for the brain was demonstrated in earlier studies in rodents, but there was considerable controversy over whether the results could be applied to humans. We hope this study helps to settle the matter."In an earlier study in rodents, researchers showed that activation of potassium channels in the brain's hypothalamus sends signals to the liver that dampen its production of glucose. Those findings, published in Nature in 2005, challenged the conventional thinking that blood sugar production by the liver (the body's glucose factory) is regulated only by the pancreas (which makes insulin to metabolize glucose). But carefully performed studies on dogs, conducted at Vanderbilt University, failed to replicate the results, suggesting the Einstein findings in rodents might not be relevant to higher mammals, including humans.The current study, involving people, was aimed at resolving this controversy. Ten nondiabetic subjects were given oral diazoxide, a drug that activates potassium channels in the hypothalamus. (The drug is not used to treat diabetes.) Hormone secretion by the pancreas was controlled to ensure that any change in sugar production would only have occurred through the drug's effect on the brain. After the researchers administered the drug, blood tests revealed that patients' livers were producing significantly less glucose than before.Hawkins and her team then repeated this in rats, again giving diazoxide orally, achieving similar results. They confirmed that sufficient amounts of diazoxide crossed the blood-brain barrier to affect potassium channels in the hypothalamus. Additional experiments confirmed that diazoxide was working through the brain. Specifically, the researchers were able to completely block the effects of diazoxide by infusing a specific potassium channel blocker directly into the brain."This study confirms that the brain plays a significant role in regulating glucose production by the liver," said lead author Preeti Kishore, assistant professor of medicine. "We are now investigating whether this 'brain-to-liver' pathway is impaired in people with diabetes. If so, we may be able to restore normal glucose regulation by targeting potassium channels in the brain."